Exploring the Efficacy of Various Immune Regulatory Approaches in Clinical Trials for Regenerative Medicine Applications

Simona Conti(Center for Integrative Biology, Università degli Studi di Trento, Via Sommarive 9, Povo-Trento, 38123, Italy)

Abstract

This review explores the efficacy of different immune regulatory approaches in clinical trials for regenerative medicine applications. Immunomodulatory therapies play a crucial role in promoting tissue repair and regeneration by modulating the immune response. Understanding the effectiveness of these approaches is essential for advancing regenerative medicine and improving patient outcomes. We conducted a comprehensive review of clinical trials evaluating various immune regulatory strategies, including mesenchymal stem cell therapy, cytokine-based immunomodulation, and immune checkpoint inhibitors. Key findings from these trials are summarized, highlighting their safety profile, efficacy in promoting tissue regeneration, and potential limitations. The review discusses the mechanisms underlying immune regulation in regenerative processes and explores the implications of these findings for future research and clinical practice. By elucidating the efficacy of immune regulatory approaches in clinical trials, this review provides valuable insights into optimizing regenerative medicine strategies for enhanced patient care.

References

Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nature Reviews Immunology. 2008 Mar;8(9):726-36.

Caplan AI. Mesenchymal stem cells. Journal of Orthopaedic Research. 1991 Sep;9(5):641-50.

Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-7.

Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Molecular Therapy. 2012 Mar 1;20(1):14-20.

Galipeau J, Sensebe L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018 Feb 1;22(6):824-33.

Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, et al. Role for interferon-γ in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006 Oct;24(2):386-98.

Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nature Reviews Immunology. 2012 Apr;12(5):383-96.

Ghannam S, Pène J, Moquet-Torcy G, Jorgensen C, Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. The Journal of Immunology. 2010 Oct 1;185(1):302-12.

Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. Annual Review of Pathology: Mechanisms of Disease. 2011 Jan 27;6:457-78.

Duffy MM, Ritter T, Ceredig R, Griffin MD. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Research & Therapy. 2011 Dec;2(4):34.

Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood. 2005 Mar 15;105(10):4120-6.

Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood. 2009 Jan 15;113(26):6576-83.

Rasmusson I, Ringdén O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Experimental Cell Research. 2005 Apr 1;305(1):33-41.

Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells. 2006 Jul;24(1):74-85.

Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005 Feb 15;105(4):1815-22.

English K, Barry FP, Mahon BP. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunology Letters. 2008 Mar 15;115(1):50-8.

François M, Romieu-Mourez R, Li M, Galipeau J. Human MSC suppression correlates with cytokine induction of indoleamine 2, 3-dioxygenase and bystander M2 macrophage differentiation. Molecular Therapy. 2012 Mar 1;20(1):187-95.

Meisel R, Zibert A, Laryea M, Gobel U, Däubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase–mediated tryptophan degradation. Blood. 2004 Jun 15;103(12):4619-21.

Chiesa S, Morbelli S, Morando S, Massollo M, Marini C, Bertoni A, et al. Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proceedings of the National Academy of Sciences. 2011 Jun 28;108(42):17384-9.

Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood. 2005 Apr 1;105(7):2821-7.

Li Y, Lin F. Mesenchymal stem cells are injured by complement after their contact with serum. Blood. 2012 Mar 15;120(17):3436-43.

Tu Z, Li Q, Bu H, Lin F. Mesenchymal stem cells inhibit complement activation by secreting factor H. Stem Cells and Development. 2010 Oct 1;19(10):1803-9.

Sudres M, Norol F, Trenado A, Grégoire S, Charlotte F, Levacher B, et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. The Journal of Immunology. 2006 Feb 15;176(12):7761-7.

Prigione I, Benvenuto F, Bocca P, Battistini L, Uccelli A, Pistoia V, et al. Reciprocal interactions between human mesenchym

DOI: http://dx.doi.org/10.26549/ahpr.v5i2.15929